Literature DB >> 25662352

Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders.

Masami Tanaka1, Masako Kinoshita2, Keiko Tanaka3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25662352     DOI: 10.1177/1352458514546793

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  6 in total

Review 1.  Immuno-pathogenesis of neuromyelitis optica and emerging therapies.

Authors:  Norio Chihara; Takashi Yamamura
Journal:  Semin Immunopathol       Date:  2022-05-30       Impact factor: 11.759

Review 2.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

3.  Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder.

Authors:  Bo Chen; Qian Wu; Gaotan Ke; Bitao Bu
Journal:  Sci Rep       Date:  2017-04-11       Impact factor: 4.379

4.  Comparison of spontaneous brain activity revealed by regional homogeneity in AQP4-IgG neuromyelitis optica-optic neuritis versus MOG-IgG optic neuritis patients: a resting-state functional MRI study.

Authors:  Junqing Wang; Yuan Tian; Yi Shao; Hui Feng; Limin Qin; Weiwei Xu; Hongjuan Liu; Quangang Xu; Shihui Wei; Lin Ma
Journal:  Neuropsychiatr Dis Treat       Date:  2017-10-24       Impact factor: 2.570

5.  Efficacy of tacrolimus as long-term immunotherapy for neuronal surface antibody-mediated autoimmune encephalitis.

Authors:  Chenchen Liu; Suqiong Ji; Huajie Gao; Zhuajin Bi; Qin Zhang; Ke Shang; Jie Cao; Bitao Bu
Journal:  Ther Adv Chronic Dis       Date:  2022-01-10       Impact factor: 5.091

6.  The Alteration of Circulating Lymphocyte Subsets During Tacrolimus Therapy in Neuromyelitis Optica Spectrum Disorder and Its Correlation With Clinical Outcomes.

Authors:  Liang Wang; Wenjuan Huang; Jingzi ZhangBao; Xuechun Chang; Hongmei Tan; Lei Zhou; Chuanzhen Lu; Min Wang; Jiahong Lu; Chongbo Zhao; Chao Quan
Journal:  Front Neurol       Date:  2022-01-19       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.